Outlook Therapeutics
OTLK
14 hedge funds and large institutions have $1.53M invested in Outlook Therapeutics in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
17% more funds holding
Funds holding: 12 → 14 (+2)
0.06% more ownership
Funds ownership: 0.03% → 0.09% (+0.06%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
29% less capital invested
Capital invested by funds: $2.15M → $1.53M (-$618K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$280K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$78.8K |
| 3 |
Renaissance Technologies
New York
|
+$78.8K |
| 4 |
PWMG
Prestige Wealth Management Group
Flemington,
New Jersey
|
+$8.9K |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
+$4.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.39M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$100K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$57K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$16.5K |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$15K |
OTLK Hedge Fund Activity: Q1 2019 in Review
14 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2019, worth a combined $1.53M — down 29% from $2.15M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new OTLK positions and 6 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was United Capital Financial Advisors, opening a new position worth an estimated $280K. The largest seller was Sabby Management, exiting entirely with an estimated $1.39M sold.
- 14 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2019, up from 12 in Q4 2018.
- Funds reported $1.53M of Outlook Therapeutics stock for Q1 2019, down 29% quarter-over-quarter.
- 8 funds opened new Outlook Therapeutics positions in Q1 2019 and 6 closed out, a net change of +2 holders.
- The largest Outlook Therapeutics buyer in Q1 2019 was United Capital Financial Advisors, an estimated $280K added.
- The largest Outlook Therapeutics seller in Q1 2019 was Sabby Management, an estimated $1.39M sold.
Based on aggregated 13F filings for Q1 2019.